Gastrointestinal, mucosal, pancreatic, and digestive signaling under study.
22 results
Blend · 3 components
This blend is examined in studies of gastric, intestinal, and pancreatic pathways.
Published evidence — exact blend
Not yet reviewed
Components (reviewed separately)
Individual peptide
Research interest in BPC-157 centres on gut-barrier integrity and digestive signaling.
Level 2 · Animal Research
Claim: Gastrointestinal and mucosal signaling
1 Laboratory2 Animal3 Early Human4 Controlled Human5 Established
Extensive rodent studies; no completed controlled human trials.
View evidence map →Blend · 4 components
Research interest in this blend centres on gut-barrier integrity and digestive signaling.
Published evidence — exact blend
Not yet reviewed
Components (reviewed separately)
Blend · 3 components
Research interest in this blend centres on gut-barrier integrity and digestive signaling.
Published evidence — exact blend
Not yet reviewed
Components (reviewed separately)
Blend · 2 components
Researchers are studying this blend in relation to gastrointestinal signaling and mucosal pathways.
Published evidence — exact blend
Not yet reviewed
Components (reviewed separately)
Blend · 2 components
This blend is examined in studies of gastric, intestinal, and pancreatic pathways.
Published evidence — exact blend
Not yet reviewed
Components (reviewed separately)
Individual peptide
Cagrilintide is examined in studies of gastric, intestinal, and pancreatic pathways.
Level 4 · Controlled Human Studies
Claim: Gastrointestinal and mucosal signaling
1 Laboratory2 Animal3 Early Human4 Controlled Human5 Established
Randomized controlled trials alone and with semaglutide.
View evidence map →Blend · 2 components
Research interest in this blend centres on gut-barrier integrity and digestive signaling.
Published evidence — exact blend
Not yet reviewed
Components (reviewed separately)
Individual peptide
Chonluten is examined in studies of gastric, intestinal, and pancreatic pathways.
Level 1 · Laboratory Research
Claim: Gastrointestinal and mucosal signaling
1 Laboratory2 Animal3 Early Human4 Controlled Human5 Established
Laboratory bioregulator work only.
View evidence map →Individual peptide
Eloralintide is examined in studies of gastric, intestinal, and pancreatic pathways.
Level 3 · Early Human Research
Claim: Gastrointestinal and mucosal signaling
1 Laboratory2 Animal3 Early Human4 Controlled Human5 Established
Early-phase human trials underway; no controlled outcome data published yet.
View evidence map →Blend · 2 components
Researchers are studying this blend in relation to gastrointestinal signaling and mucosal pathways.
Published evidence — exact blend
Not yet reviewed
Components (reviewed separately)
Individual peptide
Researchers are studying KPV in relation to gastrointestinal signaling and mucosal pathways.
Level 2 · Animal Research
Claim: Gastrointestinal and mucosal signaling
1 Laboratory2 Animal3 Early Human4 Controlled Human5 Established
Animal and cell studies of inflammatory signaling.
View evidence map →Every result card shows the same five-segment bar. Each level below matches the color of that segment.
Level 1: Laboratory Research
Observed in cells, tissue, or computational models only.
Level 2: Animal Research
Studied in animal models; results often do not transfer to people.
Level 3: Early Human Research
Human research
Small, early-stage, or uncontrolled studies in humans.
Level 4: Controlled Human Studies
Human research
Randomized or otherwise controlled human trials exist.
Level 5: Regulatory Review or Established Clinical Use
Human research
Reviewed by a regulator or established in clinical practice for a specific use.
Evidence is rated by claim—not popularity. More studies do not always mean stronger evidence.
A higher level describes research maturity. It is not a recommendation or endorsement.
Educational information only. Not medical advice.
0 peptides selected
Select up to 6 peptides to compare.